Production (Stage)
Tarsus Pharmaceuticals, Inc.
TARS
$42.98
$0.010.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.68% | 1.31% | 29.65% | 6.83% | 14.73% |
| Total Depreciation and Amortization | 6.48% | 52.11% | 18.83% | -11.48% | -22.19% |
| Total Amortization of Deferred Charges | 0.72% | 6.98% | 27.72% | -11.40% | 2.70% |
| Total Other Non-Cash Items | -5.06% | -5.57% | -22.27% | 34.93% | 25.04% |
| Change in Net Operating Assets | 66.65% | -172.42% | -22.86% | 219.36% | -205.99% |
| Cash from Operations | 6.90% | -156.38% | 39.93% | 61.88% | 3.93% |
| Capital Expenditure | -719.44% | 74.47% | 72.86% | -497.13% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.27% | -1,844.93% | 108.64% | 61.31% | -671.71% |
| Cash from Investing | 41.35% | -2,004.54% | 107.72% | 60.36% | -672.68% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,565.60% | 331.71% | -- | -- | 403.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 99.85% | -377.59% | -- |
| Cash from Financing | 4,565.60% | 358.06% | -98.49% | -61.09% | 450.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 202.71% | -1,513.69% | 61.26% | 59.64% | -1,711.13% |